Marvel Biosciences (MRVL) Stock Overview

Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company's lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. It targets diseases, such as depression, Alzheimer's disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company is headquartered in Calgary, Canada.